October 10, 2023 in NanOlogy Press Release

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer

Comments Off on Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Research article published in Pancreas ...

Read More
Post placeholder image
October 5, 2023 in Presentations

AACR Pancreatic Cancer 2023 Poster: EUS-guided Local Administration of Large Surface Area Microparticle Paclitaxel with Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer: A Single Center Experience

Comments Off on AACR Pancreatic Cancer 2023 Poster: EUS-guided Local Administration of Large Surface Area Microparticle Paclitaxel with Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer: A Single Center Experience
Read More
Post placeholder image
October 5, 2023 in Presentations

AACR Pancreatic Cancer 2023 Poster: Enhancing the Immune Response in Locally Advanced Pancreatic Cancer (LAPC) with Intratumoral Endoscopic Ultrasound-guided Fine Needle Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX)

Comments Off on AACR Pancreatic Cancer 2023 Poster: Enhancing the Immune Response in Locally Advanced Pancreatic Cancer (LAPC) with Intratumoral Endoscopic Ultrasound-guided Fine Needle Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX)
Read More
September 12, 2023 in NanOlogy Press Release

NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer

Comments Off on NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer

NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer FORT WORTH (September 12, 2023) — NanOlogy LLC, a clinica ...

Read More
June 7, 2023 in Home Page, NanOlogy Press Release

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Comments Off on NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs   FORT WORTH, Texas--NanOlogy LLC, a clinical-stage oncolog ...

Read More
March 7, 2023 in Home Page, NanOlogy Press Release

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Comments Off on NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer Covers intratumoral delivery of certain LSAM investigational ...

Read More
November 11, 2022 in Home Page, NanOlogy Press Release

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Comments Off on NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer FORT WORTH (November 11, 2022) — NanOlogy LLC, a clinical-stage inte ...

Read More
Post placeholder image
September 6, 2022 in Publications

Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies

Comments Off on Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
Read More